← Eichor
Condition: Endometrioid Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Endometrioid Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Phase 1 · 1 location(s) · Theolytics Limited · NCT07211659MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3 · 53 location(s) · Swiss GO Trial Group · NCT04111978A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Phase 1 · 7 location(s) · Light Chain Bioscience - Novimmune SA · NCT05403554Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Phase 2 · 1 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT06561308Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
Phase N/A · 1 location(s) · Mayo Clinic · NCT07062016ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT05542407A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel I
Phase 2 · 1 location(s) · University of Florida · NCT07107334Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · 409 location(s) · National Cancer Institute (NCI) · NCT05256225SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)
Phase 2 · 3 location(s) · Queensland Centre for Gynaecological Cancer · NCT06278857Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Phase 2 · 2 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06617923PROfiling Based Endometrial Cancer Adjuvant Therapy
NA · 10 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT05179447Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
Phase 2 · 2 location(s) · Roswell Park Cancer Institute · NCT05231122CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Phase 2 · 66 location(s) · TORL Biotherapeutics, LLC · NCT06690775Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal
Phase 3 · 19 location(s) · M.D. Anderson Cancer Center · NCT04575935Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05415709Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade En
Phase 2 · 1 location(s) · University College, London · NCT05080556A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologo
Phase 2 · 10 location(s) · Oncoinvent Solutions AS · NCT06504147APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurr
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT04919629Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
Phase 3 · 5 location(s) · University of Utah · NCT03422198Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Phase 3 · 676 location(s) · NRG Oncology · NCT06580314Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicente
Phase N/A · 20 location(s) · Mayo Clinic · NCT06689956Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer
NA · 1 location(s) · Peking University People's Hospital · NCT05945407Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fa
Phase 2 · 3 location(s) · Mayo Clinic · NCT06639074Trial of THEO-260 in Ovarian Cancer Patients
Phase 1/Phase 2 · 4 location(s) · Theolytics Limited · NCT06618235Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Can
Phase 2 · 9 location(s) · Aadi Bioscience, Inc. · NCT05997017Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian
Phase 1 · 2 location(s) · University of Colorado, Denver · NCT06856499Study of NTB-928 in R/R OC
Phase 1 · 2 location(s) · TeneoSeven, Inc. · NCT07690189Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Phase 2 · 137 location(s) · National Cancer Institute (NCI) · NCT05112601Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With A
Phase 2 · 18 location(s) · Faeth Therapeutics · NCT06463028
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.